Royalty Report: Drugs, Diabetes Treatment, Cancer – Collection: 351975

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Diabetes Treatment
  • Cancer
  • Therapeutic
  • Drug Discovery
  • Medical
  • Supply
  • Pharmaceuticals
  • Wound Care
  • Disease
  • obesity

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 351975

License Grant
Licensor granted Licensee of Singapore an exclusive license to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6, SON-080 (the “Compound”) (such preparations, the “Products”) for the prevention, treatment or palliation of diabetic peripheral neuropathy in humans (the “DPN Field”) in Malaysia, Singapore, Indonesia, Thailand, Philippines, Vietnam, Brunei, Myanmar, Lao PDR and Cambodia (the “Exclusive Territory”).
License Property
Compound is SON-080, a specific recombinant human interleukin-6. SON-080 is a candidate in target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Field of Use
Field of use is for the prevention, treatment or palliation of diabetic peripheral neuropathy in humans.

Peripheral neuropathy is nerve damage caused by chronically high blood sugar and diabetes. It leads to numbness, loss of sensation, and sometimes pain in your feet, legs, or hands. It is the most common complication of diabetes.

IPSCIO Record ID: 311829

License Grant
The transaction is subject to execution of a definitive agreement to be negotiated between Licensor and Licensee of Singapore to license the SON-081 and SON-080 assets as a collaboration in Diabetic Peripheral Neuropathy and Chemotherapy-Induced Peripheral Neuropathy for ASEAN Region.
License Property
SON-081 and SON-080 assets, both low-dose formulations of Interleukin 6 (IL-6). SON-081 which could help diabetic patients recover from the debilitating effects of peripheral diabetic neuropathies and SON-080 in diseases for cancer patients.

Low dose IL-6 treatment demonstrated neurorestorative properties that allowed nerve regrowth, reinstatement of physiological nerve conductance and restoration of never fiber density, which consequentially reduced pain and aberrant sensations in animals suffering from neuropathy. In addition, safety monitoring of previous clinical trials in thrombocytopenia that had enrolled more than 200 cancer patients undergoing chemotherapy concluded that low-dose IL-6 was generally safe and well tolerated. SON-081 is an identical formulation of the same low-dose IL-6, SON-080, in development for chemotherapy-induced peripheral neuropathy, where low dose IL-6 is believed to work through a similar mechanism of action for neuroprotection, nerve growth and pain reduction.

Field of Use
The Field of Use is for diabetic peripheral neuropathy (DPN) and chemotherapy-induced peripheral neuropathy (CIPN), providiing relief to patients battling chronic pain, loss of sensation and various motor neuron conditions.

Diabetic neuropathy refers to various types of nerve damage associated with diabetes mellitus.
Chemotherapy-induced peripheral neuropathy is a progressive, enduring, and often irreversible condition featuring pain, numbness, tingling and sensitivity to cold in the hands and feet (sometimes progressing to the arms and legs) that afflicts between 30% and 40% of patients undergoing chemotherapy.

IPSCIO Record ID: 279366

License Grant
Licensor hereby grants to Licensee the exclusive worldwide right and license, with the right to sublicense on the terms and conditions set forth, in the Field of Use under the Licensor Patent(s) to make, have made, market, have marketed, use, import, offer for sale, sell and have sold Licensed Product (the License). The License granted hereunder shall be subject to any rights of the U.S. Government, its agencies or authorities under Public Law 96-517 and Public Law 98-620 which may be applicable. Notwithstanding the License granted herein, Licensor shall have the right, subject to Licensees consent, not to be unreasonably withheld, to make and have made Licensed Product(s) for itself and distribution to non-profit organizations for research purposes only, but not for any commercial or other purpose. Nothing in the foregoing sentence shall constitute a grant by Licensee or confer upon Licensor any rights to make or use the Biological Materials.
License Property
Licensor Patent(s) shall mean those United States or foreign patents and/or applications listed hereto as amended and modified from time to time by Licensor is hereby incorporated herein by reference, the inventions disclosed therein, and any divisions, reissues, continuations, continuations-in-part or extensions relating or corresponding thereto, and disclosed in foreign patent application corresponding thereto.

US Application Serial No. 09/546,733  

Biological Materials shall mean the vascular endothelial growth factor-2 gene referred to as “VEGF-2” and proprietary naked plasmid DNA encoding for VEGF-2, including the plasmid DNA sometimes referred to as “phVEGF-2” or “pVGI.1(VEGF2)”, together with any Progeny, Derivatives and Modifications therefrom.

Initial Product shall mean a product for the treatment of peripheral diabetic neuropathy that incorporates Biological Materials.

Licensed Product shall mean any product or method in the Field of Use covered by one or more Valid Claims.

Intellectual Property shall mean all intellectual property rights, including (i) United States and other national patents and patent applications, divisions, continuations, continuations-in-part, reissues, renewals, reexaminations, requests for continued examination, supplemental registrations or extensions thereof, (ii) trademarks, whether registered or unregistered and applications for registration thereof, (iii) copyrights, whether registered or unregistered and applications for registration thereof, and (iv) trade secrets, know-how, technology, proprietary information and data, including formulae, procedures, plans, methods, processes, specifications, models, protocols, techniques and experimentation, and design, testing and manufacturing data, and products, compositions, and procedures.

Field of Use
Field of Use shall mean the use of Biological Materials for treating a peripheral neuropathy, including, without limitation, diabetic neuropathy.

Peripheral neuropathy refers to the conditions that result when nerves that carry messages to and from the brain and spinal cord from and to the rest of the body are damaged or diseased. The peripheral nerves make up an intricate network that connects the brain and spinal cord to the muscles, skin, and internal organs.

IPSCIO Record ID: 233450

License Grant
The Parties intend to develop in Asia a therapeutic product containing glufosfamide for the treatment of cancer.

The Japanese Licensor grants an exclusive license to Licensors Know-How to make, have made, use, offer to sell, sell and import Compound Product throughout the world.

License Property
The Compound shall mean glufosfamide.

The Compound Product shall mean any product that was developed by Licensee or a sublicensee of Licensee for marketing as a therapeutic that contains the Compound and that is for the treatment of cancer.

Field of Use
The Field shall mean all human cancer therapeutic uses.

IPSCIO Record ID: 2596

License Grant
The Company granted an exclusive license to manufacture, distribute, market and sell all of its products in a designated territory to Licensee, Jakarta, Indonesia.
License Property
The Company engages in the development, marketing and sale of primarily proprietary sprays, ointments and dressings for the management of certain chronic non-healing skin ulcerations such as pressure, diabetic and venous ulcers, surgical incisions and burns.
Field of Use
The rights granted apply to chronic wounds and wound care.

IPSCIO Record ID: 236353

License Grant
The Parties intend to develop in Asia a therapeutic product containing glufosfamide for the treatment of cancer.

The Japanese Licensor grants an exclusive license to Licensors Know-How to make, have made, use, offer to sell, sell and import Compound Product throughout the world.

License Property
The Compound shall mean glufosfamide.

The Compound Product shall mean any product that was developed by Licensee or a sublicensee of Licensee for marketing as a therapeutic that contains the Compound and that is for the treatment of cancer.

Field of Use
The Field shall mean all human cancer therapeutic uses.

IPSCIO Record ID: 253975

License Grant
Licensor of the United Kingdom grants an exclusive, even as to Licensor,  license under the Licensor Rights to research, develop, make, have made, use, sell, have sold, offer for sale and import/export Product(s) in the Field in the Territory, together with the right to grant sublicenses.
License Property
Product means any product which includes as an active pharmaceutical ingredient known as Licensors 010 or a GKA Back-up for use either alone or in combination with one or more other therapeutically active substances.  PSN010 is (2R)-2(4-cyclopropanesulfonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl) proplonamide or a salt or other derivative.

The patents include Tricyclo substituted amide compounds;  Tricyclo substituted amide glucokinase activator compounds;  Substituted phenylacetamidcs and their use as glucokinasc activators;   Enantioselective process;  Fluorination process of protected aminothiazole; and, Tricyclo Substituted Amides.

Glucokinase activators have a dual effect in the pancreas and the liver resulting in increased hepatic glucose uptake in the liver and stimulated insulin secretion by the pancreas.

Glucokinase Activator (GKA) includes the lead compound PSN010.  GKAs like PSN010 are designed to attenuate hyperglycemia by rapidly lowering blood glucose levels through a dual mechanism of increasing glucose uptake in the liver and potentiating insulin secretion from the pancreas. PSN010 is currently in Phase I clinical trials.

PSN010 was discovered and developed in-house through Licensor’s diabetes and obesity research efforts.

Field of Use
GKAs represent a new approach to diabetes therapy.

IPSCIO Record ID: 340374

License Grant
The University grants a sublicensable license that is exclusive with respect to certain patent applications and patents that may grant from the applications, and non-exclusive with respect to certain know-how, in each case to research, develop, make, have made, use, sell and import products. The license grant is worldwide.
License Property
These patents and know-how for treating and/or detecting certain inherited neuropathies, are, in particular those caused by mutation in the sorbitol dehydrogenase (SORD) gene.  SORD, the enzyme Sorbitol Dehydrogenase, is the enzyme which follows AR, or aldose reductase, in the polyol pathway and converts sorbitol to fructose.

Patients with SORD deficiency build up very high levels of sorbitol in their cells and tissues as a result of the enzyme deficiency, which results in tissue toxicities such as peripheral neuropathy and motor neuron disease.

Field of Use
The field of use is treating and/or detecting certain inherited neuropathies.

Neuropathy is damage or dysfunction of one or more nerves that typically results in numbness, tingling, muscle weakness and pain in the affected area. Neuropathies frequently start in your hands and feet, but other parts of your body can be affected too.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.